Phase-III-Studie zur Chemotherapie niedrig-maligner Non-Hodgkin-Lymphome: Vergleich einer Vincristin- mit einer Vindesin-Kombinations-Chemotherapie
- 1 January 1987
- journal article
- research article
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 10 (6) , 345-348
- https://doi.org/10.1159/000216441
Abstract
In a phase-III study in non-Hodgkin''s lymphoma of low malignancy we compared a combination therapy with vincristine (COP) with a vindesine combination (CEP). Remission rates, duration of remission and survival was favorable for the CEP combination without reaching the level of significance. The peripheral neurotoxicity of grade 2 and 3 according to WHO criteria was observed more frequently with vincristine. The vincristine-induced neurotoxicity in 6 patients was not impaired when a change was made to vindesine treatment.Keywords
This publication has 0 references indexed in Scilit: